Literature DB >> 12753397

DNA microarrays and likelihood ratio bioinformatic methods: discovery of human melanocyte biomarkers.

Thomas P Dooley1, Ernest V Curto, Richard L Davis, Paola Grammatico, Edward S Robinson, Teresa W Wilborn.   

Abstract

In this article, some of the advantages and limitations of DNA microarray technologies for gene expression profiling are summarized. As a model experiment, DermArray DNA microarrays were utilized to identify potential biomarkers of cultured normal human melanocytes in two different experimental comparisons. In the first case, melanocyte RNA was compared with vastly dissimilar non-melanocytic RNA samples of normal skin keratinocytes and fibroblasts. In the second case, melanocyte RNA was compared with a primary cutaneous melanoma line (MS7) and a metastatic melanoma cell line (SKMel-28). The alternative approaches provide dramatically different lists of 'normal melanocyte' biomarkers. The most robust biomarkers were identified using principal component analysis bioinformatic methods related to likelihood ratios. Only three of 25 robust biomarkers in the melanocyte-proximal study (i.e. melanocytes vs. melanoma cells) were coincidentally identified in the melanocyte-distal study (i.e. melanocytes vs. non-melanocytic cells). Selected up-regulated biomarkers of melanocytes (i.e. TRP-1, melan-A/MART-1, silver/Pmel17, and nidogen-2) were validated by qRT-PCR. Some of the melanocytic biomarkers identified here may be useful in molecular diagnostics, as potential molecular targets for drug discovery, and for understanding the biochemistry of melanocytic cells.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12753397     DOI: 10.1034/j.1600-0749.2003.00036.x

Source DB:  PubMed          Journal:  Pigment Cell Res        ISSN: 0893-5785


  8 in total

1.  GENE PROFILING: IMPLICATIONS IN DERMATOLOGY.

Authors:  Miroslav Blumenberg; Marjana Tomic-Canic
Journal:  Expert Rev Dermatol       Date:  2007

2.  Global profiling of genes modified by endoplasmic reticulum stress in pancreatic beta cells reveals the early degradation of insulin mRNAs.

Authors:  P Pirot; N Naamane; F Libert; N E Magnusson; T F Ørntoft; A K Cardozo; D L Eizirik
Journal:  Diabetologia       Date:  2007-03-01       Impact factor: 10.122

Review 3.  DNA microarrays: recent developments and applications to the study of pituitary tissues.

Authors:  Xiang Qian; Bernd W Scheithauer; Kalman Kovacs; Ricardo V Lloyd
Journal:  Endocrine       Date:  2005-10       Impact factor: 3.633

Review 4.  Genetic pathways to melanoma tumorigenesis.

Authors:  M R Hussein
Journal:  J Clin Pathol       Date:  2004-08       Impact factor: 3.411

5.  Induction of nuclear factor-kappaB and its downstream genes by TNF-alpha and IL-1beta has a pro-apoptotic role in pancreatic beta cells.

Authors:  F Ortis; P Pirot; N Naamane; A Y Kreins; J Rasschaert; F Moore; E Théâtre; C Verhaeghe; N E Magnusson; A Chariot; T F Orntoft; D L Eizirik
Journal:  Diabetologia       Date:  2008-05-08       Impact factor: 10.122

6.  Microarray evidence of glutaminyl cyclase gene expression in melanoma: implications for tumor antigen specific immunotherapy.

Authors:  John Stuart Gillis
Journal:  J Transl Med       Date:  2006-07-04       Impact factor: 5.531

7.  Analysis of differential gene expression in human melanocytic tumour lesions by custom made oligonucleotide arrays.

Authors:  N J W de Wit; J Rijntjes; J H S Diepstra; T H van Kuppevelt; U H Weidle; D J Ruiter; G N P van Muijen
Journal:  Br J Cancer       Date:  2005-06-20       Impact factor: 7.640

8.  PAX6 regulates melanogenesis in the retinal pigmented epithelium through feed-forward regulatory interactions with MITF.

Authors:  Shaul Raviv; Kapil Bharti; Sigal Rencus-Lazar; Yamit Cohen-Tayar; Rachel Schyr; Naveh Evantal; Eran Meshorer; Alona Zilberberg; Maria Idelson; Benjamin Reubinoff; Rhonda Grebe; Rina Rosin-Arbesfeld; James Lauderdale; Gerard Lutty; Heinz Arnheiter; Ruth Ashery-Padan
Journal:  PLoS Genet       Date:  2014-05-29       Impact factor: 5.917

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.